IBDEI0G9 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7037,1,4,0)
 ;;=4^Z96.652
 ;;^UTILITY(U,$J,358.3,7037,2)
 ;;=^5063706
 ;;^UTILITY(U,$J,358.3,7038,0)
 ;;=D69.6^^58^459^7
 ;;^UTILITY(U,$J,358.3,7038,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7038,1,3,0)
 ;;=3^Thrombocytopenia,Unspec
 ;;^UTILITY(U,$J,358.3,7038,1,4,0)
 ;;=4^D69.6
 ;;^UTILITY(U,$J,358.3,7038,2)
 ;;=^5002370
 ;;^UTILITY(U,$J,358.3,7039,0)
 ;;=L40.52^^58^459^6
 ;;^UTILITY(U,$J,358.3,7039,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7039,1,3,0)
 ;;=3^Psoriatic Arthritis Mutilans
 ;;^UTILITY(U,$J,358.3,7039,1,4,0)
 ;;=4^L40.52
 ;;^UTILITY(U,$J,358.3,7039,2)
 ;;=^5009167
 ;;^UTILITY(U,$J,358.3,7040,0)
 ;;=Q79.60^^58^459^4
 ;;^UTILITY(U,$J,358.3,7040,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7040,1,3,0)
 ;;=3^Ehlers-Danlos Syndrome,Unspec
 ;;^UTILITY(U,$J,358.3,7040,1,4,0)
 ;;=4^Q79.60
 ;;^UTILITY(U,$J,358.3,7040,2)
 ;;=^5158135
 ;;^UTILITY(U,$J,358.3,7041,0)
 ;;=Q79.61^^58^459^1
 ;;^UTILITY(U,$J,358.3,7041,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7041,1,3,0)
 ;;=3^Ehlers-Danlos Syndrome,Classical
 ;;^UTILITY(U,$J,358.3,7041,1,4,0)
 ;;=4^Q79.61
 ;;^UTILITY(U,$J,358.3,7041,2)
 ;;=^5158136
 ;;^UTILITY(U,$J,358.3,7042,0)
 ;;=Q79.62^^58^459^2
 ;;^UTILITY(U,$J,358.3,7042,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7042,1,3,0)
 ;;=3^Ehlers-Danlos Syndrome,Hypermobile
 ;;^UTILITY(U,$J,358.3,7042,1,4,0)
 ;;=4^Q79.62
 ;;^UTILITY(U,$J,358.3,7042,2)
 ;;=^5158137
 ;;^UTILITY(U,$J,358.3,7043,0)
 ;;=Q79.63^^58^459^5
 ;;^UTILITY(U,$J,358.3,7043,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7043,1,3,0)
 ;;=3^Ehlers-Danlos Syndrome,Vascular
 ;;^UTILITY(U,$J,358.3,7043,1,4,0)
 ;;=4^Q79.63
 ;;^UTILITY(U,$J,358.3,7043,2)
 ;;=^5158138
 ;;^UTILITY(U,$J,358.3,7044,0)
 ;;=Q79.69^^58^459^3
 ;;^UTILITY(U,$J,358.3,7044,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7044,1,3,0)
 ;;=3^Ehlers-Danlos Syndrome,Other
 ;;^UTILITY(U,$J,358.3,7044,1,4,0)
 ;;=4^Q79.69
 ;;^UTILITY(U,$J,358.3,7044,2)
 ;;=^5158139
 ;;^UTILITY(U,$J,358.3,7045,0)
 ;;=Z12.31^^58^460^1
 ;;^UTILITY(U,$J,358.3,7045,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7045,1,3,0)
 ;;=3^Screening Mammogram for Malig Neop Breast
 ;;^UTILITY(U,$J,358.3,7045,1,4,0)
 ;;=4^Z12.31
 ;;^UTILITY(U,$J,358.3,7045,2)
 ;;=^5062685
 ;;^UTILITY(U,$J,358.3,7046,0)
 ;;=Z12.39^^58^460^8
 ;;^UTILITY(U,$J,358.3,7046,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7046,1,3,0)
 ;;=3^Screening for Malig Neop Breast
 ;;^UTILITY(U,$J,358.3,7046,1,4,0)
 ;;=4^Z12.39
 ;;^UTILITY(U,$J,358.3,7046,2)
 ;;=^5062686
 ;;^UTILITY(U,$J,358.3,7047,0)
 ;;=Z11.51^^58^460^5
 ;;^UTILITY(U,$J,358.3,7047,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7047,1,3,0)
 ;;=3^Screening for HPV
 ;;^UTILITY(U,$J,358.3,7047,1,4,0)
 ;;=4^Z11.51
 ;;^UTILITY(U,$J,358.3,7047,2)
 ;;=^5062674
 ;;^UTILITY(U,$J,358.3,7048,0)
 ;;=Z11.59^^58^460^16
 ;;^UTILITY(U,$J,358.3,7048,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7048,1,3,0)
 ;;=3^Screening for Viral Diseases
 ;;^UTILITY(U,$J,358.3,7048,1,4,0)
 ;;=4^Z11.59
 ;;^UTILITY(U,$J,358.3,7048,2)
 ;;=^5062675
 ;;^UTILITY(U,$J,358.3,7049,0)
 ;;=Z11.3^^58^460^6
 ;;^UTILITY(U,$J,358.3,7049,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7049,1,3,0)
 ;;=3^Screening for Infections w/ Sexual Mode of Transmission
 ;;^UTILITY(U,$J,358.3,7049,1,4,0)
 ;;=4^Z11.3
 ;;^UTILITY(U,$J,358.3,7049,2)
 ;;=^5062672
 ;;^UTILITY(U,$J,358.3,7050,0)
 ;;=Z11.9^^58^460^7
